VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC Internation...(Center West Dan Greenleaf president a...),Health

Dan Greenleaf, president and CEO of VioQuest Pharmaceuticals, stated, "We are seeing meaningful clinical and biological activity in our two leading oncology drug candidates, VQD-002 and Lenocta(TM), which paves the way for the initiation of several Phase II clinical trials. For VQD-002, which we believe is the leading Akt inhibitor in clinical development, we have documented Akt modulation in both the leukemia and solid tumor trials at the 35mg/m2 dose. During this quarter, we expect to complete the Phase I portion of our VQD-002 leukemia clinical trial and initiate the Phase II expansion portion of the trial. Concurrently, we have initiated our Phase II trial for Lenocta(TM) in solid tumors. Phase I data from the trial demonstrates an increase in the activities of natural killer, CD8 and type II dendritic cells. We believe that the pace at which we are progressing clinically is indicative of the ongoing validation of the pathways, our clinical and biological data, the Company's focus, the upgrades to our clinical development team and the investigator excitement related to our development programs."

About VQD-002

VQD-002 Triciribine phosphate (TCN-PM) is a novel, first in class tricyclic nucleoside that inhibits phosphorylated Akt (protein kinase B). Akt is a serine/threonine protein kinase, which is not normally active in human cells, but is hyperphosphorylated (hyperactivated) in many tumor types. The Akt pathway has been shown to play critical roles in malignant transformation by inducing cell survival, growth, migration, angiogenesis and inhibition of apoptosis, thereby making blockage of this pathway an attractive therapeutic target. VQD-002 has demonstrated single agent strong and potent anti-tumor activities during preclinical evaluation studies and in various ongoing Phase I/II clinical studies as well. This product is in ongoing clinical studies as a single agent in both solid and hematological tumors at the Moffitt Canc
'/>"/>